We are live on ! Find out more
GALT icon

Galectin Therapeutics
GALT

76 hedge funds and large institutions have $35.4M invested in Galectin Therapeutics in 2019 Q2 according to their latest regulatory filings, with 27 funds opening new positions, 23 increasing their positions, 14 reducing their positions, and 15 closing their positions.

New
Increased
Maintained
Reduced
Closed

80% more first-time investments, than exits

New positions opened: 27 | Existing positions closed: 15

64% more repeat investments, than reductions

Existing positions increased: 23 | Existing positions reduced: 14

17% more funds holding

Funds holding: 65 → 76 (+11)

0.78% less ownership

Funds ownership: 16.03% → 15.25% (-0.78%)

5% less capital invested

Capital invested by funds: $37.3M → $35.4M (-$1.94M)

39% less call options, than puts

Call options by funds: $894K | Put options by funds: $1.46M

Holders
76
Holders Change
+11
Holders Change %
+16.92%
% of All Funds
1.65%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
27
Increased
23
Reduced
14
Closed
15
Calls
$894K
Puts
$1.46M
Net Calls
-$567K
Net Calls Change
+$105K

Top Buyers

Rank Fund Capital Flow
1
BlackRock
BlackRock
New York
+$6.28M
2
State Street
State Street
Massachusetts
+$1.81M
3
Geode Capital Management
Geode Capital Management
Massachusetts
+$820K
4
Vanguard Group
Vanguard Group
Pennsylvania
+$542K
5
AG
Advisor Group
Arizona
+$496K

Top Sellers

Rank Fund Capital Flow
1
Millennium Management
Millennium Management
New York
-$1.52M
2
Goldman Sachs
Goldman Sachs
New York
-$891K
3
LCM
Laurion Capital Management
New York
-$877K
4
CS
Credit Suisse
Switzerland
-$794K
5
JP Morgan Chase
JP Morgan Chase
New York
-$773K
Name Holding Trade Value Shares
Change 		Change in
Stake
TEE
76
Tibra Equities Europe
United Kingdom
– -$371K -72,685 Closed
ECM
77
ExodusPoint Capital Management
New York
– -$362K -70,854 Closed
GCP
78
GSA Capital Partners
United Kingdom
– -$291K -56,915 Closed
BCM
79
BlueCrest Capital Management
Jersey
– -$231K -45,280 Closed
JG
80
Jefferies Group
New York
– -$137K -26,800 Closed
Jane Street
81
Jane Street
New York
– -$113K -22,029 Closed
Citadel Advisors
82
Citadel Advisors
Florida
– -$88.4K -20,411 Closed
AGM
83
Alpine Global Management
New York
– -$98K -19,093 Closed
LWAC
84
Laurel Wealth Advisors (California)
California
– -$85K -16,600 Closed
BFM
85
Boothbay Fund Management
New York
– -$78K -15,333 Closed
Verition Fund Management
86
Verition Fund Management
Connecticut
– -$76K -14,808 Closed
BSW
87
Buckingham Strategic Wealth
Missouri
– -$51K -10,000 Closed
SWM
88
SeaCrest Wealth Management
New York
– -$10K -1,900 Closed
Fidelity Investments
89
Fidelity Investments
Massachusetts
– +$69 +16 New
1 2 3
4

GALT Hedge Fund Activity: Q2 2019 in Review

76 of the 4,604 institutional investors tracked by Wall St. Rank reported a position in Galectin Therapeutics (GALT) for Q2 2019, worth a combined $35.4M — down 5.2% from $37.3M a quarter earlier.

Buyers outnumbered sellers: 27 funds opened new GALT positions and 15 closed out — a net gain of 12 holders — while 23 added to existing stakes and 14 trimmed.

The largest buyer was BlackRock, adding an estimated $6.28M. The largest seller was Millennium Management, cutting an estimated $1.52M.

  • 76 institutional investors held Galectin Therapeutics (GALT) as of Q2 2019, up from 65 in Q1 2019.
  • Funds reported $35.4M of Galectin Therapeutics stock for Q2 2019, down 5.2% quarter-over-quarter.
  • 27 funds opened new Galectin Therapeutics positions in Q2 2019 and 15 closed out, a net change of +12 holders.
  • The largest Galectin Therapeutics buyer in Q2 2019 was BlackRock, an estimated $6.28M added.
  • The largest Galectin Therapeutics seller in Q2 2019 was Millennium Management, an estimated $1.52M sold.

Based on aggregated 13F filings for Q2 2019.